Vor Biopharma (Vor Biopharma) Cash-to-Debt : 3.85 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Vor Biopharma Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Vor Biopharma's cash to debt ratio for the quarter that ended in Dec. 2023 was 3.85.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Vor Biopharma could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Vor Biopharma's Cash-to-Debt or its related term are showing as below:

VOR' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.21 Med: 4.88 Max: No Debt
Current: 3.85

During the past 6 years, Vor Biopharma's highest Cash to Debt Ratio was No Debt. The lowest was 0.21. And the median was 4.88.

VOR's Cash-to-Debt is ranked worse than
58.54% of 1539 companies
in the Biotechnology industry
Industry Median: 6.46 vs VOR: 3.85

Vor Biopharma Cash-to-Debt Historical Data

The historical data trend for Vor Biopharma's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Vor Biopharma Cash-to-Debt Chart

Vor Biopharma Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

No Debt

2.65

11.52

5.92

3.85

Vor Biopharma Quarterly Data
	Dec18	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial														5.92	5.47	4.98	4.38	3.85

Competitive Comparison of Vor Biopharma's Cash-to-Debt

For the Biotechnology subindustry, Vor Biopharma's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vor Biopharma's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vor Biopharma's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Vor Biopharma's Cash-to-Debt falls into.

Vor Biopharma Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Vor Biopharma's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	137.175	/	(3.83	+	31.83)
	=	3.85

Vor Biopharma's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	137.175	/	(3.83	+	31.83)
	=	3.85

Vor Biopharma (NAS:VOR) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Vor Biopharma Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Vor Biopharma's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Vor Biopharma (Vor Biopharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vor Biopharma Inc (NAS:VOR) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

100 Cambridgepark Drive, Suite 101, Cambridge, MA, USA, 02140

Website

https://www.vorbio.com

Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VOR33.

Executives

Eyal C. Attar	officer: Chief Medical Officer	535 BOYLSTON STREET, BOSTON MA 02116
5am Ventures Vi, L.p.	10 percent owner	501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Kush Parmar	director, 10 percent owner	C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Ra Capital Healthcare Fund Lp	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Nathan D. Jorgensen	officer: Chief Financial Officer	C/O VOR BIOPHARMA INC., 100 CAMBRIDGEPARK DRIVE, SUITE 400, CAMBRIDGE MA 02140
Christopher Slapak	officer: Chief Medical Officer	C/O VOR BIOPHARMA INC., 100 CAMBRIDGEPARK DRIVE, SUITE 400, CAMBRIDGE MA 02140
Sadik Kassim	officer: Chief Technology Officer	C/O VOR BIOPHARMA INC., 100 CAMBRIDGEPARK DRIVE, SUITE 400, CAMBRIDGE MA 02140
Tirtha Chakraborty	officer: Chief Scientific Officer	C/O VOR BIOPHARMA INC., 100 CAMBRIDGEPARK DRIVE, SUITE 400, CAMBRIDGE MA 02140
Robert Ang	director, officer: President and CEO	C/O NEON THERAPEUTICS, 40 ERIE STREET, SUITE 110, CAMBRIDGE MA 02139
5am Partners Vi, Llc	10 percent owner	501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
David Charles Lubner	director	C/O TETRAPHASE PHARMACEUTICALS, INC., 480 ARSENAL STREET, SUITE 110, WATERTOWN MA 02472
Puretech Health Llc	10 percent owner	501 BOYLSTON STREET, SUITE 6102, BOSTON MA 02116
Daniella Beckman	director	C/O IDENIX PHARMACEUTICALS, INC., ONE KENDALL SQUARE, BLDG. 1400, CAMBRIDGE MA 02139
5am Opportunities I (gp), Llc	10 percent owner	501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
5am Opportunities I, L.p.	10 percent owner	501 SECOND STREET, SUITE 350, SAN FRANCISCO CA 94107